Compare STRIDES PHARMA SCIENCE with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs NOVARTIS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE NOVARTIS STRIDES PHARMA SCIENCE/
NOVARTIS
 
P/E (TTM) x 16.3 1,929.1 0.8% View Chart
P/BV x 1.0 25.6 3.9% View Chart
Dividend Yield % 0.5 1.7 28.2%  

Financials

 STRIDES PHARMA SCIENCE   NOVARTIS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
NOVARTIS
Mar-19
STRIDES PHARMA SCIENCE/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,147980 117.0%   
Low Rs642600 107.0%   
Sales per share (Unadj.) Rs317.2198.7 159.6%  
Earnings per share (Unadj.) Rs7.821.0 37.4%  
Cash flow per share (Unadj.) Rs25.122.3 112.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.3 17.7%  
Book value per share (Unadj.) Rs274.3307.5 89.2%  
Shares outstanding (eoy) m89.5024.69 362.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.0 70.9%   
Avg P/E ratio x114.037.7 302.6%  
P/CF ratio (eoy) x35.735.5 100.6%  
Price / Book Value ratio x3.32.6 126.9%  
Dividend payout %25.547.7 53.5%   
Avg Mkt Cap Rs m80,05819,508 410.4%   
No. of employees `0002.50.6 431.5%   
Total wages/salary Rs m4,3411,171 370.6%   
Avg. sales/employee Rs Th11,325.88,445.4 134.1%   
Avg. wages/employee Rs Th1,731.42,015.7 85.9%   
Avg. net profit/employee Rs Th280.1891.0 31.4%   
INCOME DATA
Net Sales Rs m28,3944,907 578.7%  
Other income Rs m941783 120.2%   
Total revenues Rs m29,3345,689 515.6%   
Gross profit Rs m3,965123 3,229.2%  
Depreciation Rs m1,54032 4,844.0%   
Interest Rs m1,96216 12,342.1%   
Profit before tax Rs m1,403858 163.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97340 28.6%   
Profit after tax Rs m702518 135.6%  
Gross profit margin %14.02.5 558.0%  
Effective tax rate %6.939.6 17.5%   
Net profit margin %2.510.6 23.4%  
BALANCE SHEET DATA
Current assets Rs m24,8368,055 308.3%   
Current liabilities Rs m18,9931,850 1,026.6%   
Net working cap to sales %20.6126.4 16.3%  
Current ratio x1.34.4 30.0%  
Inventory Days Days7145 157.7%  
Debtors Days Days11334 334.4%  
Net fixed assets Rs m34,289150 22,889.7%   
Share capital Rs m895123 725.3%   
"Free" reserves Rs m23,6517,469 316.7%   
Net worth Rs m24,5467,592 323.3%   
Long term debt Rs m15,5130-   
Total assets Rs m65,4379,824 666.1%  
Interest coverage x1.754.9 3.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 86.9%   
Return on assets %4.15.4 75.0%  
Return on equity %2.96.8 41.9%  
Return on capital %6.911.5 59.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69758 27,251.9%   
Fx outflow Rs m7351,326 55.4%   
Net fx Rs m14,962-1,269 -1,179.3%   
CASH FLOW
From Operations Rs m1,871-1,943 -96.3%  
From Investments Rs m5,8262,742 212.4%  
From Financial Activity Rs m-10,157-298 3,406.1%  
Net Cashflow Rs m-2,615501 -521.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 37.8 2.0 1,890.0%  
FIIs % 8.6 1.6 537.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.5 120.5%  
Shareholders   56,241 41,647 135.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 661 Points; Banking and Finance Stocks Witness Huge Selling(Closing)

Indian share markets fell sharply today, led by weak Asian equities as worries of new lockdowns to stem surging coronavirus cases kept investors cautious worldwide.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 14, 2020 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS